vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Wheels Up Experience Inc. (UP). Click either name above to swap in a different company.
Wheels Up Experience Inc. is the larger business by last-quarter revenue ($183.8M vs $177.4M, roughly 1.0× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -15.7%, a 17.4% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -10.2%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -3.4%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Wheels Up is a provider of "on demand" private aviation in the United States and one of the largest private aviation companies in the world. It was founded in 2013 by Kenny Dichter, using a membership/on-demand business model. Wheels Up members can book private aircraft from the company fleet and third-party operators using a mobile application.
PCRX vs UP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $183.8M |
| Net Profit | $2.9M | $-28.9M |
| Gross Margin | — | 14.3% |
| Operating Margin | 3.9% | -0.9% |
| Net Margin | 1.6% | -15.7% |
| Revenue YoY | 5.0% | -10.2% |
| Net Profit YoY | — | 67.0% |
| EPS (diluted) | $0.07 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $183.8M | ||
| Q3 25 | $179.5M | $185.5M | ||
| Q2 25 | $181.1M | $189.6M | ||
| Q1 25 | $168.9M | $177.5M | ||
| Q4 24 | $187.3M | $204.8M | ||
| Q3 24 | $168.6M | $193.9M | ||
| Q2 24 | $178.0M | $196.3M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-28.9M | ||
| Q3 25 | $5.4M | $-83.7M | ||
| Q2 25 | $-4.8M | $-82.3M | ||
| Q1 25 | $4.8M | $-99.3M | ||
| Q4 24 | — | $-87.5M | ||
| Q3 24 | $-143.5M | $-57.7M | ||
| Q2 24 | $18.9M | $-97.0M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 14.3% | ||
| Q3 25 | 80.9% | 6.8% | ||
| Q2 25 | 77.4% | 8.3% | ||
| Q1 25 | 79.7% | 10.8% | ||
| Q4 24 | 78.7% | 13.9% | ||
| Q3 24 | 76.9% | 13.9% | ||
| Q2 24 | 75.1% | 2.3% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | -0.9% | ||
| Q3 25 | 3.5% | -33.1% | ||
| Q2 25 | 4.7% | -31.4% | ||
| Q1 25 | 1.2% | -45.5% | ||
| Q4 24 | 13.2% | -26.0% | ||
| Q3 24 | -82.8% | -21.6% | ||
| Q2 24 | 15.9% | -40.3% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -15.7% | ||
| Q3 25 | 3.0% | -45.1% | ||
| Q2 25 | -2.7% | -43.4% | ||
| Q1 25 | 2.8% | -55.9% | ||
| Q4 24 | — | -42.7% | ||
| Q3 24 | -85.1% | -29.8% | ||
| Q2 24 | 10.6% | -49.4% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-0.04 | ||
| Q3 25 | $0.12 | $-0.12 | ||
| Q2 25 | $-0.11 | $-0.12 | ||
| Q1 25 | $0.10 | $-0.14 | ||
| Q4 24 | $0.38 | $-0.13 | ||
| Q3 24 | $-3.11 | $-0.08 | ||
| Q2 24 | $0.39 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $133.9M |
| Total DebtLower is stronger | — | $671.3M |
| Stockholders' EquityBook value | $653.9M | $-392.1M |
| Total Assets | $1.2B | $968.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $133.9M | ||
| Q3 25 | $246.3M | $125.3M | ||
| Q2 25 | $445.9M | $107.0M | ||
| Q1 25 | $493.6M | $171.8M | ||
| Q4 24 | $484.6M | $216.4M | ||
| Q3 24 | $453.8M | $115.9M | ||
| Q2 24 | $404.2M | $141.5M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $671.3M | ||
| Q3 25 | $376.7M | $766.5M | ||
| Q2 25 | $580.5M | $770.5M | ||
| Q1 25 | $583.4M | $765.8M | ||
| Q4 24 | $585.3M | $761.3M | ||
| Q3 24 | — | $596.9M | ||
| Q2 24 | — | $597.4M |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $-392.1M | ||
| Q3 25 | $727.2M | $-374.5M | ||
| Q2 25 | $757.8M | $-347.8M | ||
| Q1 25 | $798.5M | $-288.1M | ||
| Q4 24 | $778.3M | $-202.1M | ||
| Q3 24 | $749.6M | $-117.7M | ||
| Q2 24 | $879.3M | $-72.2M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $968.8M | ||
| Q3 25 | $1.3B | $973.0M | ||
| Q2 25 | $1.5B | $1.0B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.0B | ||
| Q2 24 | $1.6B | $1.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-18.4M |
| Free Cash FlowOCF − Capex | — | $-58.3M |
| FCF MarginFCF / Revenue | — | -31.7% |
| Capex IntensityCapex / Revenue | — | 21.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-259.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $-18.4M | ||
| Q3 25 | $60.8M | $-37.1M | ||
| Q2 25 | $12.0M | $-62.9M | ||
| Q1 25 | $35.5M | $-47.9M | ||
| Q4 24 | $33.1M | $37.9M | ||
| Q3 24 | $53.9M | $-16.9M | ||
| Q2 24 | $53.2M | $-25.2M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-58.3M | ||
| Q3 25 | $57.0M | $-60.4M | ||
| Q2 25 | $9.3M | $-78.6M | ||
| Q1 25 | $26.9M | $-62.6M | ||
| Q4 24 | $31.0M | $-70.2M | ||
| Q3 24 | $49.8M | $-21.9M | ||
| Q2 24 | $51.6M | $-30.8M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -31.7% | ||
| Q3 25 | 31.7% | -32.6% | ||
| Q2 25 | 5.1% | -41.5% | ||
| Q1 25 | 15.9% | -35.3% | ||
| Q4 24 | 16.6% | -34.3% | ||
| Q3 24 | 29.6% | -11.3% | ||
| Q2 24 | 29.0% | -15.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 21.7% | ||
| Q3 25 | 2.2% | 12.5% | ||
| Q2 25 | 1.5% | 8.3% | ||
| Q1 25 | 5.1% | 8.3% | ||
| Q4 24 | 1.1% | 52.8% | ||
| Q3 24 | 2.4% | 2.6% | ||
| Q2 24 | 0.9% | 2.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
UP
Segment breakdown not available.
